[Pharmacodynamic effect of a beta-blocking agent, trasicor, in normal subjects and in subjects with valvular cardiopathy].
D000433:1-Propanol / Q000494:pharmacology / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001022:Aortic Valve Insufficiency / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects*; D006332:Cardiomegaly / Q000188:drug therapy; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006352:Heart Ventricles; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000188:drug therapy*; D008946:Mitral Valve Stenosis / Q000188:drug therapy*; D010100:Oxygen / Q000097:blood*; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use; D011666:Pulmonary Valve Stenosis / Q000188:drug therapy*
D011437:Propylamines; D000433:1-Propanol; D007545:Isoproterenol; D010100:Oxygen
Effets hémodynamiques d'un agent bêta-bloquant, le Trasicor, chez le sujet normal ou atteint de cardiopathie valvulaire.